Angelica Welch

Articles

Ramalingam Weaves Through Expanding SCLC Landscape

May 23rd 2018

Suresh S. Ramalingam, MD, sheds light on the recent data with emerging agents in small cell lung cancer.

Emerging Trastuzumab Biosimilar May Promote Competition

May 22nd 2018

Elisavet Paplomata, MD, discusses ABP 980 and the impact that biosimilars may have on global access to cancer care.

Larotrectinib Inches Closer to FDA Approval for TRK+ Cancers

May 21st 2018

Anna Farago, MD, PhD, discusses the biology of larotrectinib, as well as the importance of genetic testing for molecular alterations like TRK in patients with locally advanced solid tumors.

Experts Discuss Frontline CDK4/6 Inhibitors in ER+ Breast Cancer

May 19th 2018

Dennis J. Slamon, MD, PhD, and Sara A. Hurvitz, MD, discuss the impact of CDK4/6 inhibitors in ER-positive breast cancer.

Expert Calls for Smarter Clinical Trials in Pancreatic Neoplasms

May 18th 2018

Paul E. Oberstein, MD, discusses incorporating novel agents and sequencing approaches in advanced pancreatic neoplasms.

CAR T-Cell Therapy, Checkpoint Inhibitors Making Waves Across Hematologic Malignancies

May 18th 2018

Anas Younes, MD, discusses the current and future state of CAR T-cell therapies and immune checkpoint inhibitors in the landscape of hematologic malignancies.

CDK4/6 Inhibition Shows Early Promise in Mantle Cell Lymphoma

May 18th 2018

Selina Chen-Kiang, PhD, details the research being conducted with CDK4/6 inhibitors in mantle cell lymphoma.

Wolf Emphasizes the Importance of Phrasing in Multiple Myeloma

May 17th 2018

Jeffrey Wolf, MD, emphasizes the importance of identifying risk when diagnosing patients with multiple myeloma.

NGS Established as Most Cost-Effective Genetic Test for Metastatic NSCLC

May 17th 2018

Next-generation sequencing in metastatic non-small cell lung cancer can save Center for Medicare and Medicaid Services payers $1.4 million to $2.1 million.

Genetic Testing Becoming More Widespread in Ovarian Cancer, But Challenges Remain

May 12th 2018

Mike Janicek, MD, discusses the importance of genetic testing and how the ovarian field can benefit from a better understanding of it through genetic counselors and self-education.

Expert Discusses Radiation Techniques, Genomic Testing in Prostate Cancer

May 11th 2018

James B. Yu, MD, discusses techniques with radiation therapy, potential roadblocks, and the importance of genomic testing in treating patients with prostate cancer.

Sonpavde Navigates the Evolving Bladder Cancer Landscape

May 9th 2018

Guru P. Sonpavde, MD, navigates through the treatment landscape of urothelial carcinoma.

Monk Highlights Clinical Trials in Recurrent Ovarian Cancer

May 7th 2018

Bradley J. Monk, MD, FACOG, FACS, discusses the promise of new therapies and regimens in patients with ovarian cancer in the recurrent setting.

Combinations Take Hold in Kidney Cancer

May 7th 2018

Bradley A. McGregor, MD, discusses the growth of combination therapy in the treatment of patients with kidney cancer.

Expert Explains Shifting Myeloma Paradigm

April 27th 2018

Keith Stewart, MB, ChB, discusses the role of stem cell transplant, minimal residual disease testing, and maintenance therapy in the treatment of patients with multiple myeloma.

Novel Approaches Emerge in AL Amyloidosis

April 27th 2018

Michael Rosenzweig, MD, discusses emerging treatment options for patients with immunoglobulin light chain amyloidosis such as daratumumab and NEOD001.

Lead Author Explains ASCO's Statement on Biosimilars in Oncology

April 26th 2018

Gary H. Lyman, MD, FASCO, discusses ASCO's statement outlining the organization’s commitment to education and guidance regarding the use of biosimilars in the treatment of patients with cancer.

Options Continue to Emerge for Transplant-Ineligible Multiple Myeloma

April 26th 2018

Nitya Nathwani, MD, highlights current treatment options for transplant-ineligible multiple myeloma, as well as combinations on the horizon.

Lead Investigator Discusses Nivolumab Long-Term Survival Benefit in SCCHN

April 25th 2018

Robert L. Ferris, MD, PhD, discusses the implications of the updated findings from the phase III CheckMate-141 trial in squamous cell carcinoma of the head and neck.

Immunotherapy's Role in TNBC May Be in Combination

April 24th 2018

Hatem Soliman, MD, discusses the potential role of immunotherapy in triple-negative breast cancer.